**Core Concept:**

The question is evaluating the pharmacological management of Congestive Heart Failure (CHF), a condition characterized by a reduced ability of the heart to pump blood effectively, leading to fluid accumulation in the body. In such patients, pharmacological agents are used to improve cardiac output, reduce preload and afterload, and enhance neurohormonal antagonism.

**Why the Correct Answer is Right:**

The correct answer, Digoxin, is a cardiac glycoside that has been used for many years to manage CHF. Digoxin works by inhibiting the sodium-potassium pump in cardiac myocytes, leading to increased intracellular sodium, calcium overload, and enhanced contractility. This improves cardiac output and reduces heart rate. Additionally, digoxin can inhibit the renin-angiotensin-aldosterone system (RAAS) and reduce neurohormonal activation in CHF, further improving survival.

**Why Each Wrong Option is Incorrect:**

A. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are also used to manage CHF, but they work by inhibiting the RAAS, reducing afterload, and preventing further activation of the system. They do not directly enhance cardiac contractility like digoxin does.

B. Beta-blockers, such as carvedilol, are used to manage CHF by reducing afterload and decreasing myocardial oxygen demand. However, they do not directly improve cardiac contractility like digoxin does.

C. Calcium channel blockers, like amlodipine, work by reducing afterload and decreasing myocardial oxygen demand. They do not directly improve cardiac contractility like digoxin does.

**Clinical Pearl:**

Digoxin is a valuable tool in the pharmacological management of CHF, especially in patients with reduced LVEF (left ventricular ejection fraction) and when neurohormonal activation is high. It is essential to monitor digoxin serum levels and electrolytes closely, as toxicity can lead to severe side effects and even death.

**Correct Answer:**

Correct Answer: Digoxin (Digoxin)

Digoxin is a cardiac glycoside that improves cardiac contractility, reduces heart rate, and inhibits the RAAS system, thus reducing neurohormonal activation in CHF. This combination of actions results in better cardiac output and improved survival in CHF patients. However, it is crucial to carefully monitor digoxin serum levels and electrolytes to avoid toxicity.